<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO.3)*
IDEC PHARMACEUTICALS CORPORATION
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, No Par Value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
004493701
- --------------------------------------------------------------------------------
(CUSIP Number)
Donald F. Parman, SmithKline Beecham Corporation
One Franklin Plaza, Philadelphia, PA 19102
Telephone 215-751-7633
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
February 21, 1997
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /. (A fee
is not required only if the reporting person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE> 2
SCHEDULE 13D
CUSIP NO. 857304100 PAGE 2 OF 6 PAGES
- --------------------------------------------------------------------------------
This Amendment No. 3 amends and supplements the Statement on Schedule 13D
manually filed with the Securities and Exchange Commission (the "Commission") on
April 24, 1995 (the "Initial Statement") filed jointly by SmithKline Beecham
plc, SmithKline Beecham Corporation, and S.R. One, Limited; Amendment No. 1
electronically filed on September 26, 1996; and Amendment No. 2 electronically
filed on December 13, 1996 with respect to ownership of securities of IDEC
Pharmaceuticals Corporation.
The undersigned hereby amends and supplements Item 5 of the Initial
Statement by the following information (capitalized terms used herein
without definition shall have the same meaning as set forth in the Initial
Statement.
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SmithKline Beecham plc
98-0101920
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) /x/
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
England
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES -0-
BENEFICIALLY -----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING None
PERSON -----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
-0-
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
None
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
-0-
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
<PAGE> 3
SCHEDULE 13D
CUSIP NO. 0004493701 Page 3 of 6 Pages
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SmithKline Beecham Corporation
23-1099050
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) /x/
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Pennsylvania
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES 1,105,860
BENEFICIALLY -----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING None
PERSON -----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
1,105,860
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
None
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,105,860
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.1%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
<PAGE> 4
Page 4 of 6 Pages
Item 1. Security and Issuer.
Item 2. Identity and Background.
Item 3. Source and Amount of Funds or Other Consideration.
Item 4. Purpose of Transaction.
<PAGE> 5
Page 5 of 6 Pages
Item 5. Interest in Securities of the Issuer.
(a) Amount and Percent Beneficially Owned
Registered Name No. of Shares Percent
SmithKline Beecham plc -0- 0%
SmithKline Beecham Corporation 1,105,860 6.1%
_______
TOTAL 6.1%
(b)
(c) The reporting persons sold 885,000 shares of Common Stock
in the open market in the following manner:
<TABLE>
<CAPTION>
Registered Name Transaction Date Number of Share Price Per Share
<S> <C> <C> <C>
SmithKline Beecham plc February 5, 1997 70,000 $22.50
SmithKline Beecham plc February 13, 1997 15,000 $22.25
SmithKline Beecham plc February 14, 1997 7,500 $22.375
SmithKline Beecham plc February 14, 1997 10,000 $22.50
SmithKline Beecham plc February 18, 1997 2,500 $22.375
SmithKline Beecham plc Feburary 20, 1997 2,000 $22.25
SmithKline Beecham plc February 21, 1997 60,000 $22.50
SmithKline Beecham plc February 21, 1997 150,000 $22.575
SmithKline Beecham plc February 21, 1997 100,000 $22.625
SmithKline Beecham plc February 21, 1997 145,000 $22.75
SmithKline Beecham plc February 21, 1997 38,000 $22.875
_______
600,000
SmithKline Beecham Corporation February 21, 1997 5,000 $23.00
SmithKline Beecham Corporation February 24, 1997 50,000 $23.25
SmithKline Beecham Corporation February 24, 1997 145,000 $23.625
SmithKline Beecham Corporation February 24, 1997 50,000 $24.00
SmithKline Beecham Corporation February 24, 1997 6,000 $24.25
SmithKline Beecham Corporation February 25, 1997 29,000 $24.50
SmithKline Beecham Corporation February 28, 1997 17,500 $24.50
SmithKline Beecham Corporation February 28, 1997 25,000 $24.625
SmithKline Beecham Corporation February 28, 1997 5,000 $24.750
SmithKline Beecham Corporation February 28, 1997 2,500 $24.875
_______
335,000
</TABLE>
(d)
(e)
Item 6. Contracts, Arrangements, Understandings or
Relationship With respect to Securities of the Issuer.
Item 7. Materials to be Filed as Exhibits.
<PAGE> 6
Page 6 of 6 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, the undersigned certifies that the information set forth in the
Statement is true, correct and complete.
SMITHKLINE BEECHAM PLC
By: /s/Alison M. Horler
------------------------------
Alison M. Horler
Deputy Secretary
SMITHKLINE BEECHAM CORPORATION
By: /s/Donald F. Parman
------------------------------
Donald F. Parman
Secretary
DATED: March 3, 1997
